The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
Background: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a "reversal" effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patient...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Journal of Research in Medical Sciences |
| Subjects: | |
| Online Access: | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2023;volume=28;issue=1;spage=67;epage=67;aulast=Liu |
| _version_ | 1797645534849138688 |
|---|---|
| author | Tao Liu Ping Zhou Xin Jiang Na Wang Jialing Shou Yuqiang Fang |
| author_facet | Tao Liu Ping Zhou Xin Jiang Na Wang Jialing Shou Yuqiang Fang |
| author_sort | Tao Liu |
| collection | DOAJ |
| description | Background: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a "reversal" effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. Materials and Methods: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of "complete reversal" included left ventricular end-diastolic diameter (LVEDD) ≤50 mm for females or ≤55 mm for males and left ventricular ejection fraction (LVEF) ≥45%; the criteria of "partial reversal" was the decreased rate of LVEDD (ΔLVEDD) >10% or the increase rate of LVEF (ΔLVEF) >10%; the criteria of "no reversal" included LVEDD >50 mm for females or >55 mm for males and ΔLVEDD <10%, and LVEF <45% and ΔLVEF <10%. Results: Within the follow-up period, nine patients showed "complete reversal," eight "partial reversal," and nine "no reversal." Improvements in echocardiogram parameters were the most significant in "complete reversal" patients (P < 0.001), followed by "partial reversal" and "no reversal" patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in "complete reversal" patients were the shortest, followed by "partial reversal" and "no reversal" patients. Conclusion: ACEIs or ARBs and BBs have a "complete reversal" effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response. |
| first_indexed | 2024-03-11T14:47:31Z |
| format | Article |
| id | doaj.art-f03e556f534a4de2bce1ec26ddf13144 |
| institution | Directory Open Access Journal |
| issn | 1735-1995 1735-7136 |
| language | English |
| last_indexed | 2024-03-11T14:47:31Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Research in Medical Sciences |
| spelling | doaj.art-f03e556f534a4de2bce1ec26ddf131442023-10-30T10:39:34ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362023-01-01281676710.4103/jrms.jrms_626_21The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathyTao LiuPing ZhouXin JiangNa WangJialing ShouYuqiang FangBackground: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a "reversal" effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. Materials and Methods: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of "complete reversal" included left ventricular end-diastolic diameter (LVEDD) ≤50 mm for females or ≤55 mm for males and left ventricular ejection fraction (LVEF) ≥45%; the criteria of "partial reversal" was the decreased rate of LVEDD (ΔLVEDD) >10% or the increase rate of LVEF (ΔLVEF) >10%; the criteria of "no reversal" included LVEDD >50 mm for females or >55 mm for males and ΔLVEDD <10%, and LVEF <45% and ΔLVEF <10%. Results: Within the follow-up period, nine patients showed "complete reversal," eight "partial reversal," and nine "no reversal." Improvements in echocardiogram parameters were the most significant in "complete reversal" patients (P < 0.001), followed by "partial reversal" and "no reversal" patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in "complete reversal" patients were the shortest, followed by "partial reversal" and "no reversal" patients. Conclusion: ACEIs or ARBs and BBs have a "complete reversal" effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response.http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2023;volume=28;issue=1;spage=67;epage=67;aulast=Liuangiotensin receptor blockersangiotensin-converting enzyme inhibitorsbeta-blockersdilated cardiomyopathy |
| spellingShingle | Tao Liu Ping Zhou Xin Jiang Na Wang Jialing Shou Yuqiang Fang The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy Journal of Research in Medical Sciences angiotensin receptor blockers angiotensin-converting enzyme inhibitors beta-blockers dilated cardiomyopathy |
| title | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
| title_full | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
| title_fullStr | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
| title_full_unstemmed | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
| title_short | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
| title_sort | complete reversal effect following angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta blockers after the primary diagnosis of dilated cardiomyopathy |
| topic | angiotensin receptor blockers angiotensin-converting enzyme inhibitors beta-blockers dilated cardiomyopathy |
| url | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2023;volume=28;issue=1;spage=67;epage=67;aulast=Liu |
| work_keys_str_mv | AT taoliu thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT pingzhou thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT xinjiang thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT nawang thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT jialingshou thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT yuqiangfang thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT taoliu completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT pingzhou completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT xinjiang completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT nawang completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT jialingshou completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT yuqiangfang completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy |